Cargando…

Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics

Neisseria gonorrhoeae deploys a novel immune evasion strategy wherein the lacto-N-neotetraose (LNnT) structure of lipooligosaccharide (LOS) is capped by the bacterial sialyltransferase, using host cytidine-5’-monophosphate (CMP)-activated forms of the nine-carbon nonulosonate (NulO) sugar N-acetyl-n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulati, Sunita, Schoenhofen, Ian C., Whitfield, Dennis M., Cox, Andrew D., Li, Jianjun, St. Michael, Frank, Vinogradov, Evgeny V., Stupak, Jacek, Zheng, Bo, Ohnishi, Makoto, Unemo, Magnus, Lewis, Lisa A., Taylor, Rachel E., Landig, Corinna S., Diaz, Sandra, Reed, George W., Varki, Ajit, Rice, Peter A., Ram, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668040/
https://www.ncbi.nlm.nih.gov/pubmed/26630657
http://dx.doi.org/10.1371/journal.ppat.1005290
_version_ 1782403920860020736
author Gulati, Sunita
Schoenhofen, Ian C.
Whitfield, Dennis M.
Cox, Andrew D.
Li, Jianjun
St. Michael, Frank
Vinogradov, Evgeny V.
Stupak, Jacek
Zheng, Bo
Ohnishi, Makoto
Unemo, Magnus
Lewis, Lisa A.
Taylor, Rachel E.
Landig, Corinna S.
Diaz, Sandra
Reed, George W.
Varki, Ajit
Rice, Peter A.
Ram, Sanjay
author_facet Gulati, Sunita
Schoenhofen, Ian C.
Whitfield, Dennis M.
Cox, Andrew D.
Li, Jianjun
St. Michael, Frank
Vinogradov, Evgeny V.
Stupak, Jacek
Zheng, Bo
Ohnishi, Makoto
Unemo, Magnus
Lewis, Lisa A.
Taylor, Rachel E.
Landig, Corinna S.
Diaz, Sandra
Reed, George W.
Varki, Ajit
Rice, Peter A.
Ram, Sanjay
author_sort Gulati, Sunita
collection PubMed
description Neisseria gonorrhoeae deploys a novel immune evasion strategy wherein the lacto-N-neotetraose (LNnT) structure of lipooligosaccharide (LOS) is capped by the bacterial sialyltransferase, using host cytidine-5’-monophosphate (CMP)-activated forms of the nine-carbon nonulosonate (NulO) sugar N-acetyl-neuraminic acid (Neu5Ac), a sialic acid (Sia) abundant in humans. This allows evasion of complement-mediated killing by recruiting factor H (FH), an inhibitor of the alternative complement pathway, and by limiting classical pathway activation (“serum-resistance”). We utilized CMP salts of six additional natural or synthetic NulOs, Neu5Gc, Neu5Gc8Me, Neu5Ac9Ac, Neu5Ac9Az, legionaminic acid (Leg5Ac7Ac) and pseudaminic acid (Pse5Ac7Ac), to define structural requirements of Sia-mediated serum-resistance. While all NulOs except Pse5Ac7Ac were incorporated into the LNnT-LOS, only Neu5Gc incorporation yielded high-level serum-resistance and FH binding that was comparable to Neu5Ac, whereas Neu5Ac9Az and Leg5Ac7Ac incorporation left bacteria fully serum-sensitive and did not enhance FH binding. Neu5Ac9Ac and Neu5Gc8Me rendered bacteria resistant only to low serum concentrations. While serum-resistance mediated by Neu5Ac was associated with classical pathway inhibition (decreased IgG binding and C4 deposition), Leg5Ac7Ac and Neu5Ac9Az incorporation did not inhibit the classical pathway. Remarkably, CMP-Neu5Ac9Az and CMP-Leg5Ac7Ac each prevented serum-resistance despite a 100-fold molar excess of CMP-Neu5Ac in growth media. The concomitant presence of Leg5Ac7Ac and Neu5Ac on LOS resulted in uninhibited classical pathway activation. Surprisingly, despite near-maximal FH binding in this instance, the alternative pathway was not regulated and factor Bb remained associated with bacteria. Intravaginal administration of CMP-Leg5Ac7Ac to BALB/c mice infected with gonorrhea (including a multidrug-resistant isolate) reduced clearance times and infection burden. Bacteria recovered from CMP-Leg5Ac7Ac-treated mice were sensitive to human complement ex vivo, simulating in vitro findings. These data reveal critical roles for the Sia exocyclic side-chain in gonococcal serum-resistance. Such CMP-NulO analogs may provide a novel therapeutic strategy against the global threat of multidrug-resistant gonorrhea.
format Online
Article
Text
id pubmed-4668040
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46680402015-12-10 Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics Gulati, Sunita Schoenhofen, Ian C. Whitfield, Dennis M. Cox, Andrew D. Li, Jianjun St. Michael, Frank Vinogradov, Evgeny V. Stupak, Jacek Zheng, Bo Ohnishi, Makoto Unemo, Magnus Lewis, Lisa A. Taylor, Rachel E. Landig, Corinna S. Diaz, Sandra Reed, George W. Varki, Ajit Rice, Peter A. Ram, Sanjay PLoS Pathog Research Article Neisseria gonorrhoeae deploys a novel immune evasion strategy wherein the lacto-N-neotetraose (LNnT) structure of lipooligosaccharide (LOS) is capped by the bacterial sialyltransferase, using host cytidine-5’-monophosphate (CMP)-activated forms of the nine-carbon nonulosonate (NulO) sugar N-acetyl-neuraminic acid (Neu5Ac), a sialic acid (Sia) abundant in humans. This allows evasion of complement-mediated killing by recruiting factor H (FH), an inhibitor of the alternative complement pathway, and by limiting classical pathway activation (“serum-resistance”). We utilized CMP salts of six additional natural or synthetic NulOs, Neu5Gc, Neu5Gc8Me, Neu5Ac9Ac, Neu5Ac9Az, legionaminic acid (Leg5Ac7Ac) and pseudaminic acid (Pse5Ac7Ac), to define structural requirements of Sia-mediated serum-resistance. While all NulOs except Pse5Ac7Ac were incorporated into the LNnT-LOS, only Neu5Gc incorporation yielded high-level serum-resistance and FH binding that was comparable to Neu5Ac, whereas Neu5Ac9Az and Leg5Ac7Ac incorporation left bacteria fully serum-sensitive and did not enhance FH binding. Neu5Ac9Ac and Neu5Gc8Me rendered bacteria resistant only to low serum concentrations. While serum-resistance mediated by Neu5Ac was associated with classical pathway inhibition (decreased IgG binding and C4 deposition), Leg5Ac7Ac and Neu5Ac9Az incorporation did not inhibit the classical pathway. Remarkably, CMP-Neu5Ac9Az and CMP-Leg5Ac7Ac each prevented serum-resistance despite a 100-fold molar excess of CMP-Neu5Ac in growth media. The concomitant presence of Leg5Ac7Ac and Neu5Ac on LOS resulted in uninhibited classical pathway activation. Surprisingly, despite near-maximal FH binding in this instance, the alternative pathway was not regulated and factor Bb remained associated with bacteria. Intravaginal administration of CMP-Leg5Ac7Ac to BALB/c mice infected with gonorrhea (including a multidrug-resistant isolate) reduced clearance times and infection burden. Bacteria recovered from CMP-Leg5Ac7Ac-treated mice were sensitive to human complement ex vivo, simulating in vitro findings. These data reveal critical roles for the Sia exocyclic side-chain in gonococcal serum-resistance. Such CMP-NulO analogs may provide a novel therapeutic strategy against the global threat of multidrug-resistant gonorrhea. Public Library of Science 2015-12-02 /pmc/articles/PMC4668040/ /pubmed/26630657 http://dx.doi.org/10.1371/journal.ppat.1005290 Text en © 2015 Gulati et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gulati, Sunita
Schoenhofen, Ian C.
Whitfield, Dennis M.
Cox, Andrew D.
Li, Jianjun
St. Michael, Frank
Vinogradov, Evgeny V.
Stupak, Jacek
Zheng, Bo
Ohnishi, Makoto
Unemo, Magnus
Lewis, Lisa A.
Taylor, Rachel E.
Landig, Corinna S.
Diaz, Sandra
Reed, George W.
Varki, Ajit
Rice, Peter A.
Ram, Sanjay
Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics
title Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics
title_full Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics
title_fullStr Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics
title_full_unstemmed Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics
title_short Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics
title_sort utilizing cmp-sialic acid analogs to unravel neisseria gonorrhoeae lipooligosaccharide-mediated complement resistance and design novel therapeutics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668040/
https://www.ncbi.nlm.nih.gov/pubmed/26630657
http://dx.doi.org/10.1371/journal.ppat.1005290
work_keys_str_mv AT gulatisunita utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT schoenhofenianc utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT whitfielddennism utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT coxandrewd utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT lijianjun utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT stmichaelfrank utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT vinogradovevgenyv utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT stupakjacek utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT zhengbo utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT ohnishimakoto utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT unemomagnus utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT lewislisaa utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT taylorrachele utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT landigcorinnas utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT diazsandra utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT reedgeorgew utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT varkiajit utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT ricepetera utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics
AT ramsanjay utilizingcmpsialicacidanalogstounravelneisseriagonorrhoeaelipooligosaccharidemediatedcomplementresistanceanddesignnoveltherapeutics